CNS Pharmaceuticals’ (CNSP) “Hold” Rating Reiterated at Maxim Group

Maxim Group reissued their hold rating on shares of CNS Pharmaceuticals (NASDAQ:CNSP) in a research report sent to investors on Tuesday, Marketbeat reports.

Separately, Alliance Global Partners upgraded shares of CNS Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 24th.

CNS Pharmaceuticals Price Performance

CNSP opened at $1.32 on Tuesday. The stock’s 50 day simple moving average is $3.94 and its 200 day simple moving average is $5.37. The firm has a market cap of $1.52 million, a price-to-earnings ratio of -0.02 and a beta of 2.65. CNS Pharmaceuticals has a 1 year low of $1.27 and a 1 year high of $975.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Wealthfront Advisers LLC bought a new stake in shares of CNS Pharmaceuticals in the 4th quarter worth approximately $26,000. Integrated Wealth Concepts LLC purchased a new position in CNS Pharmaceuticals during the 4th quarter valued at $30,000. Connective Capital Management LLC bought a new position in CNS Pharmaceuticals in the 4th quarter worth $34,000. XTX Topco Ltd purchased a new stake in shares of CNS Pharmaceuticals in the 4th quarter worth about $36,000. Finally, Citadel Advisors LLC bought a new stake in shares of CNS Pharmaceuticals during the 4th quarter valued at about $39,000. Institutional investors own 14.02% of the company’s stock.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.